Dec 9 (Reuters) - CVS Health (CVS) on Tuesday forecast 2026 profit above Wall Street estimates and this year's projected earnings, signalling steady progress in the health conglomerate's turnaround plan.
CVS stock rose 5% in early trading on Tuesday.
The company in October projected double-digit earnings growth for 2026 after raising its 2025 profit forecast for the third time.
"We are closing out 2025 with meaningful momentum across our businesses and we expect another year of strong earnings growth in 2026," said Chief Financial Officer Brian Newman on Tuesday.
The company forecast 2026 adjusted profit to be in the range of $7.00 to $7.20 per share, compared with analysts' average estimate of $7.16, according to data compiled by LSEG.
It, however, expects total revenue of at least $400 billion next year, below analysts' average estimate of $419.26 billion.
CVS also raised its 2025 adjusted profit forecast to $6.60 to $6.70 per share from $6.55 to $6.65 previously.
(Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
LATEST POSTS
- 1
How a cocktail of rogue storms and climate chaos unleashed deadly flooding across Asia - 2China's 1st reusable rocket explodes in dramatic fireball during landing after reaching orbit on debut flight
- 3Dental Embed Innovation: An Achievement in Helpful Dentistry
- 4France bans Muslim gathering citing risk to participants
- 5Peruvian ex-President Martin Vizcarra sentenced to 14 years in prison
- Several injured as man threatens attack on German high-speed train
- Unfathomable and Entertaining Legal disputes That Surprise everyone
- Figure out How to Streamline Eco-friendliness in Your Volvo XC40
- Palestine weekly wrap: Protests sweep West Bank after death penalty law
- King Charles shares cancer treatment update, says it's a 'personal blessing'
- The Benefits of Effective money management for Your Youngsters' Future Monetary Prosperity
- Israel halts defense sales to France, citing 'hostile attitude,' sources tell 'Post'
- Israel’s mixed messaging on Christmas draws controversy
- RFK Jr.'s handpicked vaccine panel just voted to stop recommending hepatitis B shots for all newborns. Why experts object.
